Atomo Diagnostics Launches Share Purchase Plan to Raise Capital

Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an update.

Atomo Diagnostics Ltd. has announced the opening of its Share Purchase Plan (SPP Offer), allowing eligible shareholders to acquire shares at a discounted price. The plan aims to raise up to $1,000,000, with the possibility of increasing the maximum based on demand. Participants will receive one free attaching option for each share subscribed, with the offer closing on June 23, 2025. This initiative is part of Atomo’s strategy to strengthen its financial position and support its ongoing operations in the global diagnostic market.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Ltd. is an Australian-headquartered medical device company that specializes in supplying unique, integrated rapid diagnostic test devices to the global diagnostic market. The company focuses on simplifying testing procedures, enhancing usability, and improving reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized several products internationally and has supply agreements for testing applications targeting infectious diseases such as HIV, active syphilis, and viral versus bacterial differentiation, as well as early pregnancy detection.

Average Trading Volume: 508,383

Technical Sentiment Signal: Sell

Current Market Cap: A$11.66M

For an in-depth examination of AT1 stock, go to TipRanks’ Stock Analysis page.